Increased Neutrophil to Lymphocyte Ratio(NLR) is a Sign of Disease Activity inSystemic Lupus Erythematosus Patientswith Renal Involvement


Creative Commons License

BİLEN N., ÇANKAYA E. , BİLEN Y., UYANIK A. , ERDEM F.

Journal ofNephrology Therapeutics, vol.10, no.2, pp.2-4, 2020 (Refereed Journals of Other Institutions)

  • Publication Type: Article / Article
  • Volume: 10 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.37421/jnt.2020.10.344
  • Title of Journal : Journal ofNephrology Therapeutics
  • Page Numbers: pp.2-4

Abstract

Systemic lupus erythematosus (SLE) is an idiopathic multi-systemic autoimmune disease that covers a wide array of clinical and laboratory findings. Neutrophil to lymphocyte

ratio (NLR) is a simple onsite available recently emerged inflammatory marker which is evaluated in different inflammatory conditions such as infection, athero-embolic

disease, malignancies and autoimmune disease. In this study we aimed to investigate any relation between disease activity and NLR of the SLE patients with renal

involvement.

In this study we retrospectively analyzed hematological and laboratory parameters of SLE patients with renal involvement during both in active disease and in remission

period. We investigated 36 SLE patients with renal involvement in their active and remission period of the disease.

Mean proteinuria and serum albumin level of the patients at active disease period were 5.26 ± 2.92 gr/day, 2.58 ± 0.71 gr/dl in orderly. Mean proteinuria and serum albumin

level of the patients at remission period after cessation of intensive immunosuppression were 0.77 ± 1.59 gr/day, 4.08 ± 0.58 gr/dl inorderly. Mean NLR at active disease

period of the patients was statistically significantly detected higher than at remission period (6.11 ± 5.89, 2.65 ± 1.53, p=0.00).

We detected that SLE patients with renal involvement has a high NLR during disease activation and statistically significantly lower NLR at remission period. We offer to

investigate NLR as a disease activity marker for SLE patients with renal involvement via prospective randomized large scaled studies.